Chapter 157: Four Methods — and What Amherst Actually Does With Them
Reese had the toolkit open on the table.
Amherst looked at it with the expression of someone who has encountered this specific situation before and is running a rapid assessment of whether the current version is better or worse than the previous one.
The answer was approximately equivalent, which was not a comfortable assessment.
His finger had scabbed over. The specific memory of what had produced the scab was still producing responses in his nervous system that were out of proportion to the current physical stimulus — the psychological residue of pain was, in certain ways, more persistent than the pain itself.
He looked at Reese.
He looked at the toolkit.
He said: "Before anyone touches anything — I want to explain something."
Reese waited.
"The modification I ran on the poliovirus," Amherst said. "The vaccine pathway question. You want to know if there's a viable approach. I'm going to tell you, because it's relevant to what you're trying to accomplish and because telling you is in my interest." He paused. "There are four standard approaches to vaccine development for a pathogen of this class."
Reese's posture didn't change. But the quality of his attention shifted in the specific way that people shifted when they were receiving information they needed.
Amherst organized what he was going to say with the focused efficiency of someone who had given academic presentations for twenty years and could structure technical information rapidly even under unfavorable conditions.
"First — inactivated vaccine. You render the pathogen inactive, introduce it to the immune system, the immune system develops a response, the response persists as memory. Standard approach, well-understood production methodology." He paused. "Problem: the modification I incorporated into the poliovirus includes a self-preservation sequence borrowed from the Smallpox genome. The sequence prevents standard inactivation methods from working. Any inactivation attempt that would make the pathogen safe for vaccine use destroys the immunogenic components you need. That pathway is closed."
Reese was writing.
"Second — recombinant subunit vaccine. You identify the gene segment that produces the spike protein — the structural component the immune system learns to recognize. You isolate that segment, express it in a safe culture system, produce the spike protein independently of the whole virus, make your vaccine from the purified protein." He paused. "Problem: I anticipated this approach during development. I removed the relevant gene segment from the modification. The segment isn't there to isolate." He paused. "That pathway is also closed."
Reese stopped writing.
He looked at Amherst.
"Third — viral vector vaccine," Amherst continued. "You take a harmless carrier virus — adenovirus, attenuated influenza, similar — and insert the gene for producing the spike protein into it. You infect the patient with the carrier. The carrier delivers the gene. The patient's own cellular machinery produces the spike protein. Immune response follows." He paused. "This approach has the same fundamental problem as the second. Without the spike protein gene, you have nothing to insert into the carrier vector." He paused. "Third pathway is closed for the same reason as the second."
Reese put his pen down.
He looked at Amherst with the expression of someone who has been listening carefully to a technical explanation and has arrived at the conclusion that the technical explanation has been designed to produce a specific emotional outcome in him.
"You're describing three approaches that don't work," Reese said. "Sequentially. Methodically." He paused. "What's the fourth?"
Amherst's expression had a quality in it that was not quite satisfaction and not quite something else.
"Nucleic acid vaccine," Amherst said. "mRNA or DNA. You synthesize the genetic instructions for the spike protein directly. You deliver those instructions into the patient's cells — typically via lipid nanoparticle for mRNA, various delivery mechanisms for DNA. The patient's own machinery reads the instructions and produces the spike protein. Immune response follows." He paused. "This approach doesn't require the spike protein gene to exist in the modified virus — you're synthesizing the instructions from scratch based on the original poliovirus spike protein structure." He paused. "This approach is theoretically viable."
Reese picked up the pen again.
"Theoretically," he said.
"The challenge is synthesis speed and delivery optimization," Amherst said. "The lipid nanoparticle formulation has to be precisely calibrated for pediatric immune response in this specific viral modification context. The wrong formulation produces an immune storm in a pediatric patient that's potentially worse than the disease progression." He paused. "And the synthesis requires the original poliovirus spike protein sequence as a reference. That sequence exists in the CDC's pathogen database." He paused. "Given an adequately equipped laboratory and the right reference materials, a competent team could potentially produce a viable candidate in—" He stopped.
"How long?" Reese said.
Amherst was quiet.
Reese waited.
"I could do it faster than a standard team," Amherst said. "Given my familiarity with the modification's specific genomic landscape." He paused. "But I would need the laboratory and access to the viral material from the transport cases."
Reese looked at him for a long moment.
He looked at the toolkit.
He looked at Amherst's hand, where the scabbing was visible.
He stood up and walked out.
Frank stayed in the room.
He leaned against the wall and looked at Amherst with the assessment of someone who had been listening to the entire conversation and had formed his own conclusions about it.
Amherst looked at the ceiling.
"You don't believe me," Amherst said. Not a question.
"I believe you described four real approaches accurately," Frank said. "I believe the fourth one might actually work."
"But?" Amherst said.
"But I've been in enough rooms where someone was telling me what I wanted to hear to know the specific sound of it," Frank said. "And I'm sitting with the question of why you'd tell us a pathway that works when the three before it were designed to produce despair."
Amherst looked at him.
"Maybe I decided cooperation was the better option," Amherst said.
"Maybe," Frank said. He was quiet for a moment. "Or maybe the fourth approach requires you to have direct access to the Level 4 viral material, and the other three approaches don't."
Amherst said nothing.
Frank looked at him.
"I'm going to recommend we try it anyway," Frank said. "Because the alternative is twenty thousand children with no pathway, and whatever the odds are on what you're actually planning, twenty thousand children is not a number I can do that math on." He paused. "But I want you to know that I know. Whatever it is you're actually doing in there — I know you're doing it. And I'm going to be watching."
Amherst smiled with the half of his face that was less swollen.
"You're perceptive," Amherst said. "For a driver."
"I've met a lot of interesting people," Frank said.
David was on the platform when Reese came out.
Reese's right hand had the specific quality of someone who had hit something hard recently and was managing the residual communication from that.
David looked at his hand.
"He gave you the fourth approach," David said.
Reese looked at him.
"The mRNA pathway," David said. "Synthesizing the spike protein instructions from scratch rather than extracting from the modified virus. He told you it requires the Level 4 material."
"Yes," Reese said. He was quiet for a moment. "You knew he'd get there."
"I knew the fourth approach exists," David said. "I knew it was the only one he'd offer that was technically real." He paused. "I also know what he can do once he has unsupervised access to a BSL-4 capable environment with the viral material from the transport cases."
"I know what he can do," Reese said. "I'm going to try anyway."
David looked at him.
"The children who are in the acute phase," Reese said. "The ones past the antiviral window. There's nothing for them if we don't try. The mRNA approach, if it works, addresses the progression — not the damage that's already occurred, but the progression from where they are now." He paused. "I need to try."
David was quiet for a moment.
He thought about what Harold had said — let him try, no matter how bad it can't get much worse. He thought about what Shaw had said, that forcing the issue would create fractures in the group that mattered more than the outcome of the specific decision.
He thought about the fact that Reese was going to do this regardless of what David said, and that the question was whether he did it with or without the conditions David could put around it.
"Conditions," David said.
Reese waited.
"The base's Level 4 laboratory," David said. "Not the transport cases directly — you transfer what he needs, the minimum quantity he specifies, through the airlock system under direct observation. Root monitors the laboratory cameras continuously. The airlock stays locked from outside while Amherst is working." He paused. "At the first sign that what he's producing is not what he said he was producing, we terminate the experiment. No second chances." He paused. "And House reviews everything Amherst produces before it goes anywhere near a patient."
Reese nodded.
"One more thing," David said. "The test subject — if a candidate vaccine is produced and House clears the protocol — it doesn't go to a healthy child first. It goes to the CDC's emergency pharmacology team for rapid animal model testing. Whatever results that produces informs the human trial decision." He paused. "We don't skip that step. Not for any reason."
Reese absorbed this.
"That adds time," he said.
"It does," David said. "I know what that means for the acute cases." He paused. "It's still the right sequence. If Amherst's candidate produces an immune storm in a pediatric patient, we've made the situation catastrophic rather than bad. The animal model step catches that before it reaches a child." He looked at Reese directly. "We do this correctly or we don't do it."
Reese looked at the syringe in his hand.
He looked at David.
"Correctly," he said.
"Correctly," David confirmed.
He moved aside.
Reese took the transport case.
House had been in the secondary observation room for forty minutes when David found him.
He was reviewing Amherst's academic publication record on a tablet — the specific focused reading of someone who was building a model of the person they were about to work with rather than simply reading for information.
He looked up when David came in.
"The mRNA approach," House said. "It's real. The fourth approach he described is technically sound. The spike protein synthesis from the original poliovirus reference sequence, packaged in a lipid nanoparticle formulation optimized for pediatric immune response." He paused. "The production timeline, assuming competent execution and adequate equipment, is approximately thirty-six to forty-eight hours for a viable candidate."
"And?" David said.
"And the same approach that produces a vaccine candidate can, with a modification at the lipid nanoparticle formulation stage, produce a delivery vehicle for a completely different payload," House said. He said it with the flat precision of someone who has identified something clinically significant and is not performing the significance. "The formulation work happens inside the sealed environment. The formulation work is what I can't verify from outside."
"Root has continuous camera coverage," David said. "360-degree, no blind spots."
"Cameras show me what he does with his hands," House said. "They don't show me what's in the solution." He paused. "I need spectrometry access. Whatever he produces at each stage comes through the airlock for chemical analysis before the next stage proceeds."
David looked at him.
"That's going to require equipment we don't have in the base," David said.
"I know," House said. "Make some calls. The equipment exists within thirty minutes of this location." He paused. "Harold can identify who has it. Root can facilitate the acquisition."
David sent the message to Harold.
Harold's response came back in four minutes — a pharmaceutical research facility in Midtown that had the relevant spectrometry equipment and whose facility manager had a specific vulnerability in his professional record that Root had identified and could use as leverage.
Root acquired access in eleven minutes.
The equipment arrived at the base in forty-seven.
House set it up himself, with the focused efficiency of someone who has been using laboratory equipment for twenty-five years and doesn't need instruction.
Amherst worked.
He worked with the concentration that genuine expertise produced — the specific focused calm of someone who was in the domain where they were most capable and knew it. Whatever his other qualities, his virology was real, and in the laboratory it was visible as real.
David watched through the observation window.
He watched Amherst's hands. He watched the procedural sequence — the specific steps that a legitimate mRNA vaccine development process required, whether they were being followed. He watched the points in the sequence where deviation was possible.
Root watched on the camera feed.
House analyzed each intermediate product that came through the airlock.
After the third analysis, House appeared in David's peripheral vision.
"Stage three product is consistent with what he said it was," House said. "The spike protein synthesis is proceeding correctly. The reference sequence is the original poliovirus S protein, not a modified version." He paused. "He's doing what he said he was doing."
David looked at Amherst through the glass.
"So far," David said.
"So far," House confirmed.
David kept watching.
At 3:17 AM, Reese came out of the corridor where he'd been sitting for the past several hours with the specific quality of someone who has been waiting for news and has heard news and is integrating it.
He found David on the platform.
"House cleared the stage five intermediate," Reese said. "Amherst says he's four hours from a candidate formulation."
"I know," David said. "Root texted me."
Reese sat on the platform edge — the same edge where he and David had sat with the abandoned tracks below them in what felt like a previous operational cycle rather than a few days ago.
"He might actually be making it," Reese said. "The real thing."
"He might," David said.
"You still think he's not," Reese said.
David looked at the tracks.
"I think he's a man whose purpose is the end of human civilization and who has spent fifteen years working toward that purpose with genuine commitment," David said. "I think being in a laboratory with Level 4 viral material is the closest he's been to his actual work since before Inwood." He paused. "I think what House can verify is the chemistry of what comes through the airlock. I think there are things that can be done in a sealed environment that the chemistry of the intermediate products won't reveal until the final formulation." He paused. "I think Reese is watching him every second and that Reese is good at reading people and that if Amherst does something wrong, Reese will see it." He looked at Reese. "I'm not telling you it's definitely going wrong. I'm telling you to watch him."
"I'm watching him," Reese said.
"Good," David said.
They sat on the platform for a moment in the specific quiet of the early morning hours when the base's ambient sounds had settled to their baseline and the operational urgency was temporarily in the pause between one phase and the next.
"When this is done," Reese said. "Whatever the result is. I want to talk to you about something."
"What?" David said.
"What we do with Amherst after," Reese said. "Long-term. Because whatever we get from him on the Elder question — eventually that's done and we're still holding a man who modified his own genome, released a pediatric poliovirus, and has a documented intention to continue working toward human extinction if given any opportunity to do so." He paused. "I need to know what the plan is."
David looked at the tracks.
"Federal custody," David said. "The CDC has a standing relationship with the Department of Justice for cases involving biological weapon development. Control can facilitate the transfer with a clean chain of custody that doesn't trace back to us." He paused. "Amherst goes into a federal facility that has the specific security profile for high-value biological threat detainees. He does not get laboratory access. He does not work." He paused. "What we need from him, we get before the transfer. After the transfer, he's the government's problem."
Reese was quiet.
"You're comfortable with that?" he said.
"I'm comfortable with federal custody being worse for him than anything we can provide here while keeping him available for what we need," David said. "Yes."
Reese nodded slowly.
He looked at the tracks.
He looked at David.
"Four hours," he said.
"Four hours," David confirmed.
Reese stood and went back toward the laboratory.
David stayed on the platform and looked at the tracks and thought about four hours and about what House would find when the final formulation came through the airlock.
The Machine's terminal, visible through the open workstation door, was running its continuous assessment of the city's network architecture.
It was watching twenty thousand children.
It was watching Amherst.
It was watching the Adjudicator, who was moving through her list.
It was watching Fisk.
It was watching everything it could reach.
It was back.
End of Chapter 157
[Reader Event Active]
500 Power Stones = +1 Extra Chapter
10 Reviews = +1 Extra Chapter
Thanks for reading!
20+advance chapters on P1treon Soulforger